Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers

被引:0
|
作者
An, Tianqi [1 ]
Hui, Qiu [2 ]
Zong, Hong [1 ]
Liu, Linhua [3 ]
Cao, Xinguang [4 ]
Li, Rui [5 ,6 ]
Hu, Shuang [1 ]
Liu, Yiyi [1 ]
Li, Jia [6 ,7 ]
Zhao, Ruihua [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Minist Educ, Dept HPB Surg, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[3] Guangdong Med Univ, Sch Publ Hlth, Dongguan Key Lab Environm Med, Dongguan, Peoples R China
[4] Zhengzhou Univ, Affiliated Hosp 1, Dept Digest Dis, Zhengzhou, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Dept Resp Intervent, Zhengzhou, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
[7] Zhengzhou Univ, Affiliated Canc Hosp, Dept Integrated Chinese & Western Med, Zhengzhou, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 07期
关键词
Biliary tract cancers; Anlotinib; PD-1; inhibitor; Second-line; Treatment; INTRAHEPATIC CHOLANGIOCARCINOMA; OPEN-LABEL; CHEMOTHERAPY; SURVIVAL; QUALITY; THERAPY;
D O I
10.1007/s12094-024-03425-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAnlotinib has demonstrated promising anti-tumor efficacy in various solid tumors. Additionally, there is evidence suggesting that immune therapy can enhance the systemic responses of anlotinib. This study aimed to assess the effectiveness and safety of combining anlotinib with PD-1 inhibitors compared to fluoropyrimidine-based chemotherapy as a second-line treatment option for advanced biliary tract cancers (BTCs).MethodsA total of 242 patients with BTCs were screened at the First Affiliated Hospital of Zhengzhou University from October 2015 to October 2022. Among them, 78 patients who received either anlotinib plus PD-1 inhibitors (AP) or fluoropyrimidine-based chemotherapy (FB) as second-line treatment were included in the study. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), safety, and predictive tumor biomarkers.ResultsAmong the 78 patients with BTCs, 39 patients received AP, while 39 patients were administered FB. The ORR in the AP group was 20.5%, compared to 5.1% in the FB group. The DCR was 87.2% in the AP group and 66.7% in the FB group. The AP group demonstrated significantly better ORR and DCR compared to the FB group (p = 0.042, p = 0.032). The median PFS and OS in the AP group were 7.9 months (95% CI: 4.35-11.45) and 13.9 months (95% CI: 5.39-22.41), respectively. In the FB group, the median PFS and OS were 4.1 months (95% CI: 3.17-5.03) and 13.2 months (95% CI: 8.72-17.68), respectively. The AP group exhibited significantly better median PFS than the FB group (p = 0.027). In the subgroup analysis, patients without liver metastasis had a much longer PFS in the AP group compared to the FB group (14.3 vs. 5.5 months, p = 0.016). Similarly, patients with CEA <= 5 mu g/L also demonstrated a longer PFS in the AP group compared to the FB group (8.7 vs. 3.9 months, p = 0.008).ConclusionsThe combination of anlotinib and PD-1 inhibitors demonstrated a promising clinical effect compared to fluoropyrimidine-based chemotherapy in the second-line treatment of refractory advanced BTCs. Liver metastases and CEA levels may serve as predictive factors for identifying patients who may benefit from AP therapy.
引用
收藏
页码:1647 / 1663
页数:17
相关论文
共 50 条
  • [11] Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer
    Ma, Ji
    Yao, Nan
    Lu, Jiaying
    Qu, Wanxi
    Cui, Li
    Yuan, Shiwang
    Li, Na
    Tong, Shaodong
    Qin, Zhaohui
    Yao, Yuanhu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [12] Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Zhang, Xiaojian
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 577 - 577
  • [13] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Bangyou Zuo
    Xiaobo Yang
    Xu Yang
    Jin Bian
    Junyu Long
    Dongxu Wang
    Cong Ning
    Yanyu Wang
    Ziyu Xun
    Yunchao Wang
    Xin Lu
    Yilei Mao
    Xinting Sang
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2022, 71 : 1889 - 1896
  • [14] Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
    Kim, Yunjae
    Kim, Gihyeon
    Kim, Sujeong
    Cho, Beomki
    Kim, Sang-Yeob
    Do, Eun-Ju
    Bae, Dong-Jun
    Kim, Seungil
    Kweon, Mi-Na
    Song, Joon Seon
    Park, Sang Hyoung
    Hwang, Sung Wook
    Kim, Mi-Na
    Kim, Yeongmin
    Min, Kyungchan
    Kim, Sung-Han
    Adams, Mark D.
    Lee, Charles
    Park, Hansoo
    Park, Sook Ryun
    CELL HOST & MICROBE, 2024, 32 (08)
  • [15] A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
    Zuo, Bangyou
    Yang, Xiaobo
    Yang, Xu
    Bian, Jin
    Long, Junyu
    Wang, Dongxu
    Ning, Cong
    Wang, Yanyu
    Xun, Ziyu
    Wang, Yunchao
    Lu, Xin
    Mao, Yilei
    Sang, Xinting
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 1889 - 1896
  • [16] Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study
    Wang, Peiliang
    Fang, Xiaozhuang
    Yin, Tianwen
    Tian, Hairong
    Yu, Jinming
    Teng, Feifei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [17] Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?"
    Sahai, Vaibhav
    Zalupski, Mark M.
    CANCER, 2023, 129 (07) : 1131 - 1132
  • [18] Checkpoint inhibitors in patients with advanced, refractory biliary tract cancers
    Liddell, S.
    Wintheiser, G.
    Jin, Z.
    Tran, N.
    Mahipal, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S192 - S192
  • [19] Efficacy and safety of anlotinib with PD-1 blockades in the treatment of advanced biliary tract cancer: A real-world study.
    Chen, Kehe
    Huang, Xianshi
    Yu, Lei
    Hou, Encun
    Ou, Mei
    Wang, Junping
    Huang, Xiao
    Pan, Deng
    Liu, Yu
    Huang, Min
    Zhong, Wenhe
    Pan, Zhuang
    Zhang, Shijie
    Li, Bin
    Nong, Xiansheng
    Chen, Kefan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16129 - E16129
  • [20] A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
    He, Xiaojun
    Tan, Kai
    Du, Xilin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS582 - TPS582